Drug Trial Radar · NCT04731558
Pre- Vs Postoperative Thromboprophylaxis for Liver Resection
Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,012
Planned (sponsor's estimate)
Start
Feb 10, 2021
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Helsinki University Central HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Academy of Finland; The Finnish Medical Association
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Thromboprophylaxis for liver surgery can be commenced either preoperatively or postoperatively. Despite a clear trade-off between thrombosis and bleeding in liver surgery patients, there is no international consensus when thrombosis prophylaxis should be commenced in patients undergoing liver surgery. As far as we know, there are no prospective randomized trials in this field, and current guidelines are unfortunately based on very low quality evidence, that is, a few retrospective studies and expert opinion. Both American and European thromboprophylaxis guidelines for abdominal cancer surgery support the preoperative initiation of thromboprophylaxis, but these guidelines do not specifically address the increased bleeding risk associated with liver surgery. On the contrary, Dutch guidelines recommend postoperative thromboprophylaxis only, because of lack of evidence for preoperative thromboprophylaxis. Traditionally, many liver surgery units have been reluctant in using preoperative thromboprophylaxis due to the potentially increased risk of bleeding complications. Enhanced Recovery After Surgery (ERAS) Society Guidelines recommend preoperative thromboprophylaxis in liver surgery, but the guidelines provide no supporting evidence for this recommendation. Overall, the amount of evidence is scarce and somewhat contradictory in this clinically relevant field of thromboprophylaxis in liver surgery. The aim of this study is to compare pre- and postoperatively initiated thromboprophylaxis regimens in liver surgery in a randomized controlled trial.
Conditions
- Liver Cancer
- Surgery
- Thrombosis, Deep Vein
- Embolism, Pulmonary
- Bleeding
Interventions
enoxaparin or tinzaparin or dalteparinDrug
Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function
No interventionDrug
No preoperative thromboprophylaxis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Venous thromboembolismsTime frame: within 30 days from liver resection
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Helsinki University Hospital
Helsinki, Finland · Recruiting
Kuopio University Hospital
Kuopio, Finland · Recruiting
Oulu University Hospital
Oulu, Finland · Not yet recruiting
Tampere University Hospital
Tampere, Finland · Recruiting
Turku University Hospital
Turku, Finland · Not yet recruiting
Oslo University Hospital
Oslo, Norway · Recruiting
University Hospital of North Norway
Tromsø, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.